Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04743960
Other study ID # 2020P003741
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 5, 2021
Est. completion date October 24, 2022

Study information

Verified date January 2024
Source Massachusetts General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether advancing the timing of home parenteral nutrition from overnight to daytime regimens leads to improved glucose profiles and sleep quality, and other changes in plasma metabolic signatures.


Description:

Emerging evidence suggests that considering the time-of-day in clinical care may optimize health, partly through limiting sleep disruption and circadian misalignment. Acute sleep and circadian rhythms disturbances are associated with cardiometabolic derangements, including persistent hyperglycemia, a significant contributor to life-threatening complications. However, it is currently considered standard practice for patients on parenteral nutrition to be fed for 12-hour periods overnight. Current guidelines lack explicit guidance regarding the time-of-day when nutrition support should be administered. Thus, the overall objective of the clinical trial is to comprehensively examine a novel dimension of clinical nutrition by determining whether advancing the timing of home parenteral nutrition from overnight to daytime regimens leads to improved glucose profiles and sleep quality, and other changes in plasma metabolic signatures. The study is a 2-week controlled cross-over feeding trial where 20 short bowel syndrome patients will follow their usual overnight parenteral nutrition regimen for one week, and then advance their feeds to daytime for a second week. Patients will be assessed objectively using non-invasive, novel technologies and 'omics techniques. The investigators hypothesize that advancing the timing of home parenteral nutrition feeds to a daytime regimen is a cost-efficient, effective, and feasible nutrition timing countermeasure against metabolic derangements, fragmented sleep, and decreased quality of life. Results of this study may provide evidence-based, cost-efficient, and effective nutrition support countermeasures against hyperglycemia and sleep disruption, and could potentially modify current widespread clinical nutrition support practice.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date October 24, 2022
Est. primary completion date October 24, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 79 Years
Eligibility Inclusion Criteria: - Adult male or non-pregnant female volunteers (age 18-79) - Short bowel syndrome diagnosis - Able and willing to give consent and comply with study procedures - Currently on routine home parenteral nutrition (at least 6 months) Exclusion Criteria: - Blind, deaf or unable to speak English - Women who are pregnant or nursing - Diabetes diagnosis or currently taking or intending to take any diabetes medication or medications influencing sugars including oral glucocorticoids, growth hormone, erythropoietin, or chemotherapeutic - Current use of sleep medication and melatonin - With skin condition that precludes wearing sensors - Within the last year, bariatric surgery or pregnancy - Within the last one month, acute infections or illnesses requiring medical attention, hospitalizations, Emergency Department visits, blood transfusions, blood loss, blood donations - Major changes in diet or physical activity level in the past 3 months - Sleep and circadian disorders (such as obstructive sleep apnea and delayed sleep phase syndrome) - Anticipated barriers or challenges to daytime and/or overnight cycled infusions

Study Design


Intervention

Dietary Supplement:
Time-of-day of parenteral nutrition provision
Parenteral nutrition will be provided during the nighttime followed by daytime.

Locations

Country Name City State
United States Massachusetts General Hospital Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Massachusetts General Hospital ASPEN Rhoads Research Foundation

Country where clinical trial is conducted

United States, 

References & Publications (2)

Dashti HS, Leong A, Mogensen KM, Annambhotla M, Li P, Deng H, Carey AN, Burns DL, Winkler MF, Compher C, Saxena R. Glycemic and sleep effects of daytime compared with those of overnight infusions of home parenteral nutrition in adults with short bowel syn — View Citation

Rahmoune A, Winkler MF, Saxena R, Compher C, Dashti HS. Comparison between self-reported and actigraphy-derived sleep measures in patients receiving home parenteral nutrition: Secondary analysis of observational data. Nutr Clin Pract. 2023 Oct 1. doi: 10.1002/ncp.11077. Online ahead of print. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in 24-hour average glucose from nighttime to daytime feeds Glucose will be continuously measured using continuous glucose sensors. Blood glucose will be averaged during each of the two 1-week feeding regimens (nighttime and daytime). Average values from days 1 to 7 (nighttime feeds) and days 8 to 14 (daytime feeds).
Primary Change in number of interruptions of sleep by physical movement assessed by actigraphy from nighttime to daytime feeds Sleep will be objectively measured from actigraphy. The number of interruptions of sleep by physical movement will be calculated as 100 × the number of groups of consecutive mobile 30-s epochs/by the total number of immobile epochs. This measure will reflect sleep quality. Actigraphy data from days 1 to 7 (nighttime feeds) and days 8 to 14 (daytime feeds).
Secondary Change in area under-the-curve of glucose from nighttime to daytime feeds Glucose will be continuously measured using continuous glucose sensors. Area under-the-curve of blood glucose during the 12-hour feeds will be calculated using the trapezoid method and adjusted for baseline glucose values. Area under-the-curve of glucose will be averaged for each of the two 1-week feeding regimens (nighttime and daytime). Glucose values from days 1 to 7 (nighttime feeds) and days 8 to 14 (daytime feeds) during 12-hour cycled feeds.
Secondary Change in average daily duration of glucose levels above 140 mg/dl from nighttime to daytime feeds Glucose will be continuously measured using continuous glucose sensors. Duration of glucose levels above 140 mg/dl will be averaged during each of the two 1-week feeding regimens (nighttime and daytime). Average values from days 1 to 7 (nighttime feeds) and days 8 to 14 (daytime feeds).
Secondary Change in fasting insulin concentration from nighttime to daytime feeds Serum insulin will be measured from fasting blood samples collected on day 8 and 15. Blood draw scheduled on days 8 and 15.
Secondary Change in sleep duration from nighttime to daytime feeds Sleep duration will be objectively measured from actigraphy and sleep logs. Duration will be averaged will be averaged during each of the two 1-week feeding regimens (nighttime and daytime). Average values from days 1 to 7 (nighttime feeds) and days 8 to 14 (daytime feeds).
Secondary Change in sleep midpoint from nighttime to daytime feeds Sleep midpoint will be objectively measured from actigraphy and sleep logs. Midpoint will be averaged will be averaged during each of the two 1-week feeding regimens (nighttime and daytime). Average values from days 1 to 7 (nighttime feeds) and days 8 to 14 (daytime feeds).
Secondary Change in midpoint of least-active 5h timing from nighttime to daytime feeds Measure of sleep timing as determined from actigraphy. Timing will be averaged will be averaged during each of the two 1-week feeding regimens (nighttime and daytime). Average values from days 1 to 7 (nighttime feeds) and days 8 to 14 (daytime feeds).
Secondary Change in midpoint of most-active 10h timing from nighttime to daytime feeds Measure of sleep timing as determined from actigraphy. Timing will be averaged will be averaged during each of the two 1-week feeding regimens (nighttime and daytime). Average values from days 1 to 7 (nighttime feeds) and days 8 to 14 (daytime feeds).
See also
  Status Clinical Trial Phase
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Recruiting NCT06079853 - Nurse Suicide: Physiologic Sleep Health Promotion Trial N/A
Completed NCT05017974 - Research on Improving Sleep During Pregnancy N/A
Recruiting NCT05206747 - Ottawa Sunglasses at Night for Mania Study N/A
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT04513743 - Ultra Long-Term Sleep Monitoring Using UNEEG™ Medical 24/7 EEG™ SubQ N/A
Completed NCT03251274 - Bath Machine on Sleep Quality in Nursing Home N/A
Completed NCT04102345 - Lavender vs Zolpidem Sleep Quality During Diagnostic PSG Early Phase 1
Completed NCT03725943 - Comparison of Dreem to Clinical PSG for Sleep Monitoring in Healthy Adults N/A
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Completed NCT04562181 - Consistency Evaluation of the qCON, qNOX Indices and Bispectral Index N/A
Completed NCT05102565 - A Dyadic Telehealth Program for Alzheimer's Patients/Caregivers N/A
Completed NCT05576844 - Ai Youmian (Love Better Sleep) for People Living With HIV N/A
Completed NCT04688099 - Synovial Fluid Sleep Study
Recruiting NCT04171245 - Prescribing Laughter for Sleep and Wellbeing in UAE University Students N/A
Completed NCT03758768 - The Effects of a Blue Monochromatic Light Intervention on Evening-type Individuals' Sleep and Circadian Rhythms N/A
Completed NCT03163498 - Evaluation of Sleep Pattern and Mood Profile in Hypertensive Patients
Completed NCT04093271 - Investigating the Efficacy of Rest-ZZZ Formula in Healthy Participants With Difficulty Falling Asleep or Staying a Sleep Phase 1
Completed NCT03673397 - The Acute Effect of Aerobic Exercise on Sleep in Patients With Depression N/A
Completed NCT04120363 - Trial of Testosterone Undecanoate for Optimizing Performance During Military Operations Phase 4